Search Results - "Walter, Adam"

Challenges Faced by U.S. Student Veterans Transitioning to a Community College

Authors: Walter, Adam M.

Source: ProQuest LLC. 2019Ed.D. Dissertation, Walden University.

Peer Reviewed: N

Page Count: 191

Descriptors: Community Colleges, Veterans, Two Year College Students, Case Studies, College Freshmen, Student Adjustment, Military Service, Dropouts, Stopouts, Models, Self Concept, Student Personnel Services, Student Attitudes, Educational Environment, Educational Experience, Educational Strategies, College Faculty, Teacher Attitudes, Mentors, Friendship, Faculty Development, Withdrawal (Education)

Access URL: https://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqm&rft_dat=xri:pqdiss:13882463

Synthesis of titanate-based lepidocrocite nanostructures by reacting TiC, TiB2, and TiN with NaOH or KOH at 95 °C under ambient pressure.

Authors: Schwenk, Gregory R. Walter, Adam D. Badr, Hussein O. et al.

Source: Ceramics International. Dec2023:Part A, Vol. 49 Issue 24, p40001-40010. 10p.

Subjects: Titanates, Titanium nitride, Titanium carbide, Nanostructures, Solar cells, Titanium dioxide

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.

Authors: Walter, Adam Rocconi, Rodney P. Monk, Bradley J. et al.

Source: Gynecologic Oncology. Dec2021, Vol. 163 Issue 3, p459-464. 6p.

Post-intensive care unit syndrome in gynecologic oncology patients.

Authors: Gunderson, Camille Walter, Adam Ruskin, Rachel et al.

Source: Supportive Care in Cancer. Nov2016, Vol. 24 Issue 11, p4627-4632. 6p.

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer.

Authors: Nemunaitis, John Stanbery, Laura Walter, Adam et al.

Source: Oncology Reviews. 2023, p1-4. 4p.

Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study.

Authors: Ade, Carl J. Dockery, Lauren Walter, Adam C. et al.

Source: Nutrition & Cancer. 2023, Vol. 75 Issue 2, p662-669. 8p. 3 Charts, 2 Graphs.

Central nervous system metastasis in gynecologic cancer: Symptom management, prognosis and palliative management strategies.

Authors: Walter, Adam C. Gunderson, Camille C. Vesely, Sara K. et al.

Source: Gynecologic Oncology. Mar2015, Vol. 136 Issue 3, p472-477. 6p.

Does Perfadex Affect Outcomes In Clinical Lung Transplantation?

Authors: Nath, Dilip S. Walter, Adam R. Johnson, Adam C. et al.

Source: Journal of Heart & Lung Transplantation. Dec2005, Vol. 24 Issue 12, p2243-2248. 6p.

FIDELITY'S END: A FABLE.

Authors: Walter, Adam

Source: Dappled Things; Christmas 2011, Vol. 7 Issue 1, p77-81, 5p

3D engineered scaffold for large-scale Vigil immunotherapy production.

Authors: Kerneis, Fabienne Bognar, Ernest Stanbery, Laura et al.

Source: Scientific Reports. 7/5/2024, Vol. 14 Issue 1, p1-9. 9p.

Patient experiences blurred vision with 2-day headache.

Authors: Walter, Adam M.¹ awalter@brummeye.com

Source: Primary Care Optometry News. Jan2009, Vol. 14 Issue 1, p26-24. 2p.

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer.

Authors: Coleman, Robert L. Rocconi, Rodney Monk, Bradley J. et al.

Source: JCO Precision Oncology. 1/14/2026, Vol. 10, p1-10. 10p.

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer.

Authors: Bailey, Morgan Morand, Susan Royfman, Rachel et al.

Source: International Journal of Molecular Sciences. Mar2024, Vol. 25 Issue 6, p3173. 21p.

Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response.

Authors: Nemunaitis, John Stanbery, Laura Willoughby, David et al.

Source: Cancers. Dec2023, Vol. 15 Issue 23, p5616. 28p.

Advances in Targeted Therapy for the Treatment of Cervical Cancer.

Authors: Watkins, Dean E. Craig, Daniel J. Vellani, Shahnaz D. et al.

Source: Journal of Clinical Medicine. Sep2023, Vol. 12 Issue 18, p5992. 14p.

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.

Authors: Rocconi, Rodney P. Monk, Bradley J. Walter, Adam et al.

Source: Gynecologic Oncology. Jun2021, Vol. 161 Issue 3, p676-680. 5p.

BRIEFS

Authors: Brad Walter, Adam Pengilly

Source: Sydney Morning Herald, The. 03/10/2014.

A week on, hysteria is replaced by mild agitation

Authors: BRAD WALTER, ADAM COOPER and MICHAEL LYNCH

Source: Sydney Morning Herald, The. 02/15/2013.

Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.

Authors: Sonavane, Manoj Hedlich-Dwyer, Jenna Dal Zotto, Valeria L. et al.

Source: Gynecologic Oncology. Jan2025, Vol. 192, p65-72. 8p.

Current Ovarian Cancer Maintenance Strategies and Promising New Developments.

Authors: Gogineni, Vinaya Morand, Susan Staats, Hannah et al.

Source: Journal of Cancer. 2021, Vol. 12 Issue 1, p38-53. 16p.